Wes Streeting is facing a critical decision regarding the potential implementation of universal testing for a severe muscle deteriorating condition in newborns, which has been described as a political choice. The Health Secretary recently engaged with Giles Lomax, the CEO of SMA UK, and Jesy Nelson, a former member of the group Little Mix, who both have twins diagnosed with spinal muscular atrophy (SMA) at a later stage. Giles Lomax has directly appealed to Mr. Streeting through the Mirror, emphasizing the urgency of the situation by highlighting that delayed action results in more infants being diagnosed late.

Individuals suffering from SMA have a defective SMN1 gene, responsible for producing a crucial protein that sustains the nerve cells’ health, aiding in transmitting signals between the brain, spinal cord, and muscles. Without this protein, motor neurons perish, leading to the inability of muscles to receive movement signals, eventually wasting away.

Currently, the NHS offers three treatments that can address the faulty gene or provide a substitute for the essential protein, effectively serving as a cure if administered promptly at birth to prevent irreversible muscle damage. However, an estimated 33 babies in the UK are diagnosed too late annually, necessitating the use of wheelchairs or medical devices for breathing and feeding.

Mr. Streeting has indicated his interest in potentially expanding an NHS pilot program aimed at screening select newborns for SMA to encompass all infants through the routine NHS heel prick test. The existing pilot scheme proposes excluding around 163,000 newborns in England, forming a control group to assess the effectiveness of SMA screening, a decision criticized by experts as unethical.

Giles Lomax stressed the importance of nationwide newborn screening for SMA to ensure equal access to testing for all infants regardless of their location, emphasizing that delays in decision-making lead to more infants facing late diagnoses. The UK National Screening Committee (UKNSC) previously opted against including SMA in the newborn screening program in 2018, but with recent advancements in treatments, the committee’s reluctance to immediately introduce a £5 blood test for SMA at birth has been challenged.

While a full-scale screening rollout is not anticipated until 2031 based on the current timeline, NHS Scotland has proceeded with plans to incorporate SMA screening into their routine tests starting in the spring, contrasting with the exclusion of screening in Wales and Northern Ireland. SMA UK advocates argue that a comprehensive screening program is essential, citing international evidence that such initiatives save lives and reduce healthcare costs.

In response to the advocacy efforts, Wes Streeting acknowledged the compelling arguments for enhanced screening measures and reported progress towards a large-scale trial within the NHS, aiming to include hundreds of thousands of infants in SMA screening from the upcoming year. He expressed a commitment to exploring the possibility of accelerating the evaluation process and extending it to encompass all newborns, with the ultimate goal of ensuring that children with SMA not only survive but thrive with the available treatments.